# Post-PV myelofibrosis (spent phase)

Source: https://onco.cc/terms/post-pv-myelofibrosis/  
OnCo record `post-pv-myelofibrosis` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The late stage some people with polycythaemia vera reach after many years, when the marrow scars over, the red count falls and the spleen swells. It is treated as myelofibrosis.

## Summary

Over one to two decades a minority of PV patients progress to post-PV myelofibrosis: marrow fibrosis, falling haemoglobin, a large spleen, constitutional symptoms and sometimes transformation to acute leukaemia. Risk rises with age, duration of disease, high white cell counts and additional mutations such as ASXL1 and SRSF2. Management follows myelofibrosis: JAK inhibitors for spleen and symptoms, momelotinib for anaemia, and allogeneic stem cell transplant for fit higher-risk patients. Preventing this transition is the main long-term goal of PV research.

## Fields

- Kind: Term
- Last checked: 2026-09-16
- Tags: polycythaemia-vera; mpn

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Myelofibrosis
- Wikipedia: https://en.wikipedia.org/wiki/Myelofibrosis

## Connected records

- cancers: [Essential thrombocythaemia (ET)](https://onco.cc/cancers/essential-thrombocythaemia/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Polycythaemia vera (PV)](https://onco.cc/cancers/polycythaemia-vera/)
- drugs: [Momelotinib](https://onco.cc/drugs/momelotinib/), [Ruxolitinib](https://onco.cc/drugs/ruxolitinib/)

---
JSON: https://onco.cc/api/v1/entities/post-pv-myelofibrosis.json